LB Pharmaceuticals has granted Christopher Zergebel, its new Senior Vice President of Clinical Operations, an inducement equity award of 75,000 stock options. The options have a ten-year term, an exercise price of $32.95 per share, and vest over four years. This grant is part of the Nasdaq Listing Rule 5635(c)(4) inducement exception to attract key talent. LB Pharmaceuticals is advancing its lead drug candidate LB-102 for neuropsychiatric disorders, with ongoing Phase 3 and Phase 2 clinical trials targeting schizophrenia and bipolar depression.
Bitcoin surged past the Short-Term Holder Realized Price of $67,000-$69,000 for the first time since May, signaling a potential shift in market momentum. The Long-Term Holder Realized Price remained steady near $49,200, indicating no major sell-off f...
On January 30, 2026, Kevin Warsh was nominated as Federal Reserve Chair, triggering a sharp crypto market sell-off due to expectations of higher interest rates and aggressive balance-sheet cuts. Bitcoin dropped 7% from $84.6k to $78.7k, with $2.4 bil...
Strategy holds 840,447 Bitcoin, about 4% of total supply, valued at $64.86 billion as Bitcoin trades near $77,175, creating an unrealized gain of $1.5 billion over its $63.36 billion acquisition cost. CEO Michael Saylor emphasizes Bitcoin as "digital...
Solana has launched a governance vote on proposal SGP-0002 to double its annual disinflation rate from 15% to 30%, accelerating the reduction of new SOL token issuance. This change could cut the projected six-year SOL supply by 18.9 million tokens, w...
XRP has seen a major rally in South Korea, capturing 32.20% of Upbit's trading volume during a period when the exchange processed about $830 million in just one hour. Upbit's 24-hour turnover reached approximately $3.81 billion, with Bithumb also rep...
